NEW YORK (GenomeWeb News) – Genisphere said today it has licensed its 3DNA Signal Amplification technology to Chembio Diagnostics.
Chembio will use the technology for its Dual Path Platform rapid diagnostic pipeline tests in order to achieve detection limits "unique to rapid immunoassays, thereby broadening potential applications of its technology by combining it with the Genisphere technology," Hatfield, Penn.-based Genisphere said.
Its 3DNA Dendrimer technology can provide up to 100-fold improvement in sensitivity without increasing the assay's complexity, it said, adding that the improvement enables point-of-care analyses that has not been possible with conventional technologies.
Today's deal follows a feasibility study in which Genisphere demonstrated 3DNA Dendrimer can be adapted to Chembio's Dual Path Platform.
Financial and other terms were not disclosed.